High‐throughput screening for prescribing cascades among real world statin initiators
Pharmacoepidemiology and Drug Safety · 2023
DOI: 10.1002/pds.5607 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2023. Verfasst von Scott M Vouri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: UF College of Pharmacy.
Abstract (Originalsprache)
Purpose
Statins are among the most prevalent medications prescribed and associated with adverse events that may prompt additional treatment (i.e., a prescribing cascade). No comprehensive assessment of statin‐related prescribing cascades has been performed to our knowledge.
Methods
We utilized sequence symmetry analysis to iteratively screen prescribing sequences of all therapeutic classes (“marker” classes) based on Level 4 Anatomical Therapeutic Chemical codes among adult statin initiators, using IBM Marketscan commercial and Medicare supplemental claims databases (2005–2019). Order of initiation and secular trend‐adjusted sequence ratios were calculated for each statin‐marker class dyad, among marker class initiators ±90 days of statin initiation. Among signals classified as prescribing cascades, we calculated naturalistic number needed to harm (NNTH) within 1 year as the inverse of the excess risk among exposed.
Results
We identified 2 265 519 statin initiators (mean ± SD age, 56.4 ± 12.0 years; 48.7% women; 7.5% with cardiovascular disease). Simvastatin (34.4% of statin initiators) and atorvastatin (33.9%) were the most commonly initiated statins. We identified 160 significant statin‐marker class dyad signals, of which 35.6% ( n = 57) were classified as potential prescribing cascades. Of the top 25 strongest signals (lowest NNTH), 12 were classified as potential prescribing cascades, including osmotically acting laxatives (NNTH, 44, 95% CI 43–46), opioids + non‐opioid combination analgesics (81, 95% CI 74–91), and first‐generation cephalosporins (204, 95% CI 175–246).
Conclusions
Using high‐throughput sequence symmetry analysis screening, we identified previously known prescribing cascades as well as potentially new prescribing cascades based on known and unknown statin‐related adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.
- Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
- Center for Integrative Cardiovascular and Metabolic Disease, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: Scott M Vouri, Earl J Morris, Marta Walsh, Carl J Pepine, Steven M Smith
Förderung
- UF College of Pharmacy
Zitieren
APA
Vouri, S. M., Morris, E. J., Walsh, M., Agalliu, J., Dempsey, A., Hochleitner, L., Muschett, M. R., Schmidt, S., Pepine, C. J., & Smith, S. M. (2023). High‐throughput screening for prescribing cascades among real world statin initiators. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5607
Vancouver
Vouri SM, Morris EJ, Walsh M, Agalliu J, Dempsey A, Hochleitner L, et al. High‐throughput screening for prescribing cascades among real world statin initiators. Pharmacoepidemiology and Drug Safety. 2023. doi:10.1002/pds.5607
BibTeX
@article{Vouri2023,
author = {Vouri, Scott M and Morris, Earl J and Walsh, Marta and Agalliu, Jessica and Dempsey, Alyssa and Hochleitner, Leonie and Muschett, Matthew R and Schmidt, Stephan and Pepine, Carl J and Smith, Steven M},
title = {High‐throughput screening for prescribing cascades among real world statin initiators},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2023},
doi = {10.1002/pds.5607}
}
EUVIMED